DYRK1A and acute lymphoblastic leukemia: To determine if DYRK1A inhibition sensitizes KMT2A-R ALL cells to BCL2 inhibition, we treated KMT2A-R ALL cells in vitro with increasing concentrations of EHT1610 and the BCL2 inhibitor venetoclax and observed synergistic killing (Fig. 6C) and decreased cell viability, as assessed by flow cytometry (Fig. 6D and Supplementary Fig. 4B).